CeQur raises CHF31.7mm in Series A financing

Deal summary reprinted from Strategic Transactions - December, 2009

CeQur SA (insulin delivery systems for managing Type II diabetes) has closed its Series A round, raising a total of CHF31.7mm ($29.6mm) from BMC Ventures, Endeavour Vision, Schroder & Co. Bank, and Venture Incubator. Reas more...

CeQur raises CHF31.7mm in Series A financing

Deal summary reprinted from Strategic Transactions - December, 2009

The two-year-old company will use the proceeds to gain the CE mark and launch in Europe its lead product, the CeQur insulin patch infuser. It will also continue submitting the device for US regulatory approval. CeQur is a discreet wearable device designed to help people with Type II diabetes obtain glycemic control without the need for multiple, daily insulin injections. The product secures to a patient's abdomen where it provides up to three days of continuous subcutaneous basal insulin delivery via a cannula from the disposable reservoir, which is attached to a reusable electronic messenger. It can also deliver bolus insulin at the push of a button.

-----------------------------------------------------------------

Learn about new colon cancer screening solutions that promise to less invasive and sensitive than traditional colonoscopy with this new 55-page Special Report from Medtech Insight:" Find out more...

Find out more about what our Strategic Transactions - The Device Deal Database can do for you.

Strategic Transactions - The Device Deal Database provides expanded information, including:

- Comprehensive Deal Records
- Complete Financial Information
- Extensive Company Profiles
- Access to important SEC Documents
- Links to related articles

Contact: James DeFalco at: +1 (203) 838-4401 x104 or [email protected]